SCHEMBL1103328

SCHEMBL1103328

c1ccc(N2c3ccccc3N(c3c4ccccc4c(N4c5ccccc5N(c5ccccc5)c5ccccc54)c4c3cnc3ccccc34)c3ccccc32)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.38
KDM4E B2RXH2 2/20 0.35
GPR3 P46089 1/20 0.35
GRM5 P41594 3/20 0.34
ALDH1A1 P00352 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
NPC1 O15118 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
NFKB1 P19838 1/20 0.34
HTT P42858 1/20 0.34
RAB9A P51151 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
TLR7 Q9NYK1 1/20 0.34
GRM4 Q14833 3/20 0.33
KCNH2 Q12809 2/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103312 0.82 KDM4E (0.35) KDM4EGPR3GRM5TLR7PDE4A
SCHEMBL1103323 0.82 MPO (0.35) KDM4EGPR3GRM5SMN1; SMN2HTT
SCHEMBL1103321 0.82 MPO (0.35) KDM4EGPR3GRM5HPGDTLR7
SCHEMBL1103326 0.82 TLR7 (0.35) ADORA3KDM4EGPR3GRM5TLR7
SCHEMBL1103313 0.81 CDK4 (0.36) KDM4EGPR3GRM5ALDH1A1SMN1; SMN2
SCHEMBL1103317 0.81 MAOA (0.35) KDM4EGPR3SMN1; SMN2GAAMAPT
SCHEMBL1103316 0.79 PDPK1 (0.35) KDM4EGPR3ALDH1A1SMN1; SMN2GAA
SCHEMBL1103334 0.77 KDM4E (0.31) KDM4EGPR3GRM5
SCHEMBL1103349 0.73 ADORA3 (0.34) ADORA3KDM4EGPR3MAPTGRM4
SCHEMBL1103442 0.73 TLR7 (0.35) KDM4EALDH1A1SMN1; SMN2NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 ADORA3 2542/4885KDM4E 3367/4885GPR3 1503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.